Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Current Liabilities (2018 - 2025)

Arcturus Therapeutics Holdings' Total Current Liabilities history spans 8 years, with the latest figure at $36.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 44.45% year-over-year to $36.4 million; the TTM value through Dec 2025 reached $36.4 million, down 44.45%, while the annual FY2025 figure was $36.4 million, 44.45% down from the prior year.
  • Total Current Liabilities reached $36.4 million in Q4 2025 per ARCT's latest filing, up from $31.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $127.0 million in Q4 2022 to a low of $31.7 million in Q3 2025.
  • Average Total Current Liabilities over 5 years is $80.1 million, with a median of $84.8 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: surged 322.07% in 2021, then crashed 57.2% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $99.5 million in 2021, then grew by 27.57% to $127.0 million in 2022, then plummeted by 35.43% to $82.0 million in 2023, then decreased by 20.12% to $65.5 million in 2024, then crashed by 44.45% to $36.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Total Current Liabilities are $36.4 million (Q4 2025), $31.7 million (Q3 2025), and $46.5 million (Q2 2025).